신장암 치료제 시장 : 암 유형별, 치료별, 약제 클래스별, 투여 경로별, 유통 채널별, 세계 예측(2024-2032년)

Kidney Cancer Drugs Market size will record 5.6% CAGR from 2024-2032, driven by the growing emphasis on patient-centric approaches in drug development and treatment protocols.

The recent advances in genomic profiling and biomarker research are paving the way for personalized medicine in kidney cancer treatment. For instance, in December 2023, Belzutifan, a HIF-2a inhibitor, was approved by the U.S. FDA for treating patients suffering from advanced kidney cancer that was previously treated with anti-angiogenic therapies and immune checkpoint inhibitors. The rising efforts to develop cost-effective treatments, implement pricing strategies, and expand insurance coverage will also influence the market growth.

The kidney cancer drugs industry is segmented into cancer type, therapy, drug class, route of administration, distribution channel, and region.

By cancer type, the industry value from the Wilms tumor segment will register lucrative growth between 2024 and 2032. As Wilms tumor is a pediatric cancer, its treatment creates a specific demand for pediatric oncology drugs. To that end, several pharmaceutical companies are developing and marketing drugs tailored for children. This surging need to treat pediatric cancers is leading to improvements in healthcare infrastructure, such as specialized pediatric oncology centers, adding to the segment growth.

In terms of route of administration, the kidney cancer drugs market size from the intravenous segment is expected to record significant expansion through 2032. Intravenous (IV) administration allows effective delivery of higher concentrations of the drugs directly into the bloodstream, leading to better efficacy in treating advanced and metastatic kidney cancer. Oncologists also prefer IV drugs for certain patients, especially those who have difficulty with oral medications given their side effects or other medical conditions.

Asia Pacific kidney cancer drugs industry share will register substantial CAGR through 2032, led by rapid advances in treatment options and the increasing consumer awareness. Significant investments in clinical trials and research initiatives are leading to the development of innovative drugs tailored to the genetic profiles of patients in the region. The surging rate of kidney cancer incidence and the subsequent demand for effective drugs along with the growing regulatory support will favor the regional product uptake.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of kidney cancer
    • 3.2.1.2 Rising awareness and early diagnosis initiatives
    • 3.2.1.3 Technological advancements
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Renal cell carcinoma (RCC)
• 5.3 Transitional cell cancer
• 5.4 Wilms tumor
• 5.5 Renal sarcoma

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Targeted therapy
• 6.3 Immunotherapy
• 6.4 Chemotherapy
• 6.5 Other therapies

Chapter 7 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Angiogenesis inhibitors
• 7.3 Monoclonal antibodies
• 7.4 mTOR inhibitors
• 7.5 Cytokine immunotherapy (IL-2)
• 7.6 Other drug classes

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Intravenous
• 8.4 Subcutaneous

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Brick and mortar
• 9.4 E-commerce

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Active Biotech AB
• 11.2 Amgen, Inc.
• 11.3 Astellas Pharma Inc.
• 11.4 AstraZeneca PLC
• 11.5 Bayer AG
• 11.6 Bristol-Myers Squibb Company
• 11.7 Eisai Co., Ltd.
• 11.8 Exelixis, Inc.
• 11.9 F. Hoffmann-La Roche Ltd.
• 11.10 Genentech, Inc.
• 11.11 GSK plc
• 11.12 Helsinn Healthcare SA
• 11.13 Johnson & Johnson Services, Inc.
• 11.14 Merck & Co., Inc.
• 11.15 Novartis AG